The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period. The growth of this market is mainly driven by a rise in demand for biologics & biosimilars, the increasing collaborations among pharmaceutical companies for outsourced manufacturing, the demand for biologics and focus on personalized medicine, and advancements in manufacturing technologies. Further, factors such as growing expansions of manufacturing capabilities among biopharmaceutical manufacturers are likely to uplift market growth in the coming years.
The prominent players operating in the biotechnology contract manufacturing market are Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), and AbbVie, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
Lonza will be a leader in the biotechnology contract manufacturing market in 2022. The company offers a wide range of contract manufacturing services such as biologics drug substance and drug product manufacturing and cGMP manufacturing of cell and gene therapies. Lonza maintained its top position in the biotechnology contract manufacturing market through its strong portfolio of contract manufacturing services, advanced manufacturing facilities, strong geographic presence, and investments in the expansion of manufacturing capabilities. For instance, in February 2023, Lonza expanded its bioconjugation facility in Visp, Switzerland. This added development and manufacturing capacity for pre-clinical, clinical, and commercial supply of bioconjugates and antibody-drug conjugates.
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher Scientific, Inc. (US) will be one of the leading players in the biotechnology contract manufacturing market in 2022. The company’s leading position is attributed to its diversified service portfolio, adoption of organic and inorganic growth strategies, and strong geographic reach. The company has adopted different growth strategies, such as collaborations, agreements, and acquisitions. The company focused on expanding its manufacturing facilities across emerging countries. For example, In January 2023, the company expanded its global biologics and sterile manufacturing capabilities in Hangzhou, China. This supported the pharma services demand from China as well as the Asia Pacific region.
WuXi Biologics (China)
WuXi Biologics is a prominent company that offers a wide range of services for the biotechnology contract manufacturing market. With a strong presence in developing countries, the company captured a significant share of the market. The company’s comprehensive range of services, combined with its expertise in the field, positioned it as a leading player in the biotechnology contract manufacturing market. The company also focuses on inorganic growth strategies such as acquisitions and collaborations. For instance, in March 2021, WuXi Biologics acquired CMAB Biopharma Group from CBC Group. This added 7000L drug substance capacity and drug product capacity for liquid and lyophilization.
Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE